Johnson & Johnson
Pays vs peer median
×1.05
+5% premium
Sample
28
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.23 | 11 |
| immunology | ×1.50 | 4 |
| dermatology | ×1.06 | 4 |
| hematology | ×0.83 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×1.39 | 8 |
| preclinical | ×1.07 | 7 |
| phase 3 | ×0.70 | 5 |
| phase 1 | ×1.38 | 4 |
| approved | ×1.03 | 4 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | TD-1473 | Theravance | IBD | unknown | $100M | $1.0B |
| 2025 | Anti-FLT3 | Denali Therapeutics | MDS | phase_2 | $124M | $1.2B |
| 2025 | MUC1-001 | Beam Therapeutics | Gastric | approved | $405M | $2.2B |
| 2025 | Anti-CDK4/6-201 | Zai Lab | Ovarian | phase_2 | $504M | $5.0B |
| 2025 | ALK | PMV Pharmaceuticals | ALL | phase_2 | $301M | $2.6B |
| 2025 | MET-mab | Deciphera Pharmaceuticals | NSCLC | phase_3 | — | $634M |
| 2025 | DLL3-001 | Nurix Therapeutics | GBM | discovery | $45M | $868M |
| 2025 | CDK4/6-201 | Nektar Therapeutics | Head & Neck | preclinical | $57M | $606M |
| 2025 | CEA-201 | CRISPR Therapeutics | GBM | approved | $2.2B | $8.9B |
| 2025 | mTOR-301 | Affimed | Pancreatic | phase_3 | $969M | $7.0B |
| 2025 | KP-723 | Kaken | atopic dermatitis | preclinical | — | $1.2B |
| 2025 | KP-723 | Kaken | atopic dermatitis | preclinical | — | $1.2B |
| 2025 | Caplyta (lumateperone) acquisition | Intra-Cellular Therapies | Schizophrenia, bipolar depression, MDD | approved | $14.6B | $14.6B |
| 2025 | KP-723 | Kaken Pharmaceutical | atopic dermatitis | preclinical | — | $1.2B |
| 2025 | STAT6 inhibitor | Kaken Pharmaceutical | atopic dermatitis/asthma | preclinical | — | $1.2B |
How this is computed
For each Johnson & Johnson deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 28 disclosed deal premiums vs. peer medians. Raw premium 1.048, clamped to [0.7, 1.5].